ANDON HEALTH(SZ:002432) 3 6 Ke·2025-08-26 00:04Core Insights - Konomai (Beijing) Technology Co., Ltd. has completed A+ round financing of several tens of millions, led by Jiuan Medical, to accelerate commercialization and continue independent R&D [1][2] - The Chinese analytical instrument market heavily relies on imports, with annual import value around $100 billion, particularly in liquid chromatography, which is the leading product in chemical analysis and life sciences [1] - Konomai, established in 2019, focuses on the independent R&D and industrialization of ultra-high-performance liquid chromatography (UHPLC) technology, with a core founding team averaging nearly 20 years of experience in life science instruments [1][2] Company Developments - Konomai has completed a full series layout of UHPLC products, including automated IVD two-dimensional liquid chromatography systems and intelligent chromatography data management systems [1] - The company has initiated the construction of a production base in Suzhou since 2022, achieving a domestic component localization rate of 95% [2] - Konomai's sales revenue has been growing at over 50% annually since the start of its commercialization layout in 2023, with overseas market growth exceeding 80% [2] Investment Perspective - Jiuan Medical aims to discover and collaborate with practical enterprises that can address industry pain points and lead industrial upgrades, focusing on deepening independent R&D and leveraging the "Stanford model" [3] - The company emphasizes the importance of the domestic scientific instrument localization trend and policy support to promote import substitution in the global market [3] - Konomai's breakthroughs in the UHPLC field are breaking the long-standing reliance on imports in China's high-end market [3]